← Leaderboards
Tim M. Townes
University Of Alabama At Birmingham
$14,044,439
Attributed
$14,044,439
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $916.7K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$19,517,573 · 9
By mechanism
R01$12,764,494 · 5
P60$6,321,514 · 2
P30$395,315 · 1
R03$36,250 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Josef T Prchal$8,723,783
- Thomas M Ryan$5,321,710
- Sylvie Mrug$7,272,386
- David W Kimberlin$10,865,588
- Andrea L Cherrington$20,834,622
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaGlobinTranscription FactorLaboratory MouseHematopoietic Stem CellsGene TherapyGenetically Modified AnimalsGene ExpressionDisease /Disorder ModelBeta GlobinGenesTransfection /Expression VectorCellsAdultGene Induction /RepressionBeta ThalassemiaErythrocytesErythroid CellsGenetic Regulatory ElementNonhuman Therapy EvaluationProgramsGenetic TransductionLentivirusBone Marrow
Grant awards (47)
Human Globin Gene Regulation During Development$219,750
R01 · FY2015 · DK · contact PI
Gene Replacement Therapy for Sickle Cell Disease$422,422
R01 · FY2014 · HL · contact PI
Human Globin Gene Regulation During Development$219,750
R01 · FY2014 · DK · contact PI
Gene Replacement Therapy for Sickle Cell Disease$410,354
R01 · FY2013 · HL · contact PI
Human Globin Gene Regulation During Development$212,059
R01 · FY2013 · DK · contact PI
Gene Replacement Therapy for Sickle Cell Disease$431,044
R01 · FY2012 · HL · contact PI
Human Globin Gene Regulation During Development$219,750
R01 · FY2012 · DK · contact PI
Gene Replacement Therapy for Sickle Cell Disease$431,044
R01 · FY2011 · HL · contact PI
Gene Replacement Therapy for Sickle Cell Disease$438,699
R01 · FY2010 · HL · contact PI
Erythroid Krupple-Like Factor Complexes Defined in TAP-Tagged Knockin Mice$377,971
R01 · FY2010 · DK · contact PI
Erythroid Krupple-Like Factor Complexes Defined in TAP-Tagged Knockin Mice$100,000
R01 · FY2010 · DK · contact PI
Mouse Model of Sickle Cell Disease and Genetic Therapies$445,682
R01 · FY2009 · HL · contact PI
Erythroid Krupple-Like Factor Complexes Defined in TAP-Tagged Knockin Mice$370,668
R01 · FY2009 · DK · contact PI
Gene Replacement Therapy in Induced Pluripotent Stem (iPS) Cells for Treatment of$36,250
R03 · FY2009 · HL · contact PI
Mouse Model of Sickle Cell Disease and Genetic Therapies$426,051
R01 · FY2008 · HL · contact PI
Erythroid Krupple-Like Factor Complexes Defined in TAP-Tagged Knockin Mice$359,874
R01 · FY2008 · DK · contact PI
Mouse Model of Sickle Cell Disease and Genetic Therapies$422,085
R01 · FY2007 · HL · contact PI
Erythroid Krupple-Like Factor Complexes Defined in TAP-Tagged Knockin Mice$356,527
R01 · FY2007 · DK · contact PI
Mouse Model of Sickle Cell Disease and Genetic Therapies$422,029
R01 · FY2006 · HL · contact PI
Genetic Modifers of Sickle Cell Disease$581,956
R01 · FY2005 · HL
Genetic Modifers of Sickle Cell Disease$581,956
R01 · FY2004 · HL
Transactivation of Fetal Hemoglobin Genes for Treatment*$340,638
R01 · FY2004 · HL
Genetic Modifers of Sickle Cell Disease$581,956
R01 · FY2003 · HL
A MODEL FOR SICKLE CELL DISEASE &GENETIC THERAPIES$358,750
R01 · FY2003 · HL
Transactivation of Fetal Hemoglobin Genes for Treatment*$340,638
R01 · FY2003 · HL
Transactivation of Fetal Hemoglobin Genes for Treatment*$23,200
R01 · FY2003 · HL
COMPREHENSIVE SICKLE CELL CENTER$1,682,456
P60 · FY2002 · HL
Genetic Modifers of Sickle Cell Disease$581,956
R01 · FY2002 · HL
MOUSE MODEL FOR SICKLE CELL DISEASE &GENETIC THERAPIES$358,750
R01 · FY2002 · HL
COMPREHENSIVE SICKLE CELL CENTER$300,000
P60 · FY2002 · HL
GLOBIN GENE EXPRESSION DURING DEVELOPMENT$298,863
R01 · FY2002 · HL
Transactivation of Fetal Hemoglobin Genes for Treatment*$273,938
R01 · FY2002 · HL
GENETIC STRATEGIES FOR CORRECTING SICKLE CELL DISEASE$228,564
P60 · FY2002 · HL
GENETIC STRATEGIES FOR CORRECTING SICKLE CELL DISEASE$228,564
P60 · FY2002 · HL
PILOT--SILENCING OF TRANSGENES BY HISTONE DEACETYLASE$165,355
P30 · FY2002 · DK
COMPREHENSIVE SICKLE CELL CENTER$1,755,211
P60 · FY2001 · HL
Genetic Modifers of Sickle Cell Disease$581,956
R01 · FY2001 · HL
MOUSE MODEL FOR SICKLE CELL DISEASE &GENETIC THERAPIES$358,750
R01 · FY2001 · HL
GLOBIN GENE EXPRESSION DURING DEVELOPMENT$290,157
R01 · FY2001 · HL
Transactivation of Globin Genes$284,813
R01 · FY2001 · HL
GENETIC STRATEGIES FOR CORRECTING SICKLE CELL DISEASE$228,564
P60 · FY2001 · HL
PILOT--SILENCING OF TRANSGENES BY HISTONE DEACETYLASE$165,355
P30 · FY2001 · DK
COMPREHENSIVE SICKLE CELL CENTER$1,735,467
P60 · FY2000 · HL
MOUSE MODEL FOR SICKLE CELL DISEASE &GENETIC THERAPIES$358,750
R01 · FY2000 · HL
GLOBIN GENE EXPRESSION DURING DEVELOPMENT$281,708
R01 · FY2000 · HL
GENETIC STRATEGIES FOR CORRECTING SICKLE CELL DISEASE$162,688
P60 · FY2000 · HL
PILOT--SILENCING OF TRANSGENES BY HISTONE DEACETYLASE$64,605
P30 · FY2000 · DK